Zealand Pharma A/S (OTCMKTS:ZLDPF) Issues Quarterly Earnings Results, Beats Expectations By $1.45 EPS

Zealand Pharma A/S (OTCMKTS:ZLDPF) issued its earnings results on Thursday. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($1.57) by $1.45, Zacks reports. Zealand Pharma A/S had a net margin of 58.86% and a return on equity of 17.56%.

Zealand Pharma A/S Stock Down 3.7%

Shares of OTCMKTS ZLDPF traded down $1.35 during midday trading on Thursday, hitting $35.50. 515 shares of the company’s stock were exchanged, compared to its average volume of 2,350. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.98 and a quick ratio of 13.98. Zealand Pharma A/S has a twelve month low of $33.08 and a twelve month high of $83.12. The company has a market cap of $2.54 billion, a PE ratio of 5.89 and a beta of 0.99. The firm’s fifty day simple moving average is $38.85 and its 200-day simple moving average is $46.81.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. Wells Fargo & Company reissued an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday, August 13th. Barclays cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 8th. Finally, Zacks Research downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, Zealand Pharma A/S has an average rating of “Hold”.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a biotechnology company headquartered in Copenhagen, Denmark. Founded in 1998, it discovers and develops peptide-based medicines, with a focus on metabolic diseases and rare conditions. The company’s portfolio has included Zegalogue (dasiglucagon), an injectable treatment approved in the United States for severe hypoglycemia in people with diabetes. Zealand also develops investigational medicines for areas such as obesity, liver disease and rare gastrointestinal disorders, and works with pharmaceutical partners to advance and commercialize selected programs.